Assembly Biosciences (ASMB) Cash & Equivalents (2010 - 2026)

Assembly Biosciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $31.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 32.92% year-over-year to $31.1 million in Q1 2026; TTM through Mar 2026 was $31.1 million, a 32.92% increase from a year earlier, with the FY2025 full-year figure at $58.4 million, up 52.44% from the prior year.
• Cash & Equivalents eased to $31.1 million in Q1 2026 per ASMB's latest filing, from $58.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $58.4 million in Q4 2025 and bottomed at $18.1 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $28.5 million (2024), against an average of $33.9 million.
• Across the five-year window, Cash & Equivalents sank 62.15% in 2023 and soared 93.26% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $52.4 million in 2022, then sank by 62.15% to $19.8 million in 2023, then surged by 93.26% to $38.3 million in 2024, then soared by 52.44% to $58.4 million in 2025, then sank by 46.76% to $31.1 million in 2026.
• Per Business Quant, the three latest ASMB Cash & Equivalents figures stand at $31.1 million (Q1 2026), $58.4 million (Q4 2025), and $22.5 million (Q3 2025).